Content area

Abstract

Increases in the world’s population and population density promote the spread of emerging pathogens. Vaccines are the most cost-effective means of preventing this spread. Traditional methods used to identify and produce new vaccines are not adequate, in most instances, to ensure global protection. New technologies are urgently needed to expedite large scale vaccine development. mRNA-based vaccines promise to meet this need. mRNA-based vaccines exhibit a number of potential advantages relative to conventional vaccines, namely they (1) involve neither infectious elements nor a risk of stable integration into the host cell genome; (2) generate humoral and cell-mediated immunity; (3) are well-tolerated by healthy individuals; and (4) are less expensive and produced more rapidly by processes that are readily standardized and scaled-up, improving responsiveness to large emerging outbreaks. Multiple mRNA vaccine platforms have demonstrated efficacy in preventing infectious diseases and treating several types of cancers in humans as well as animal models. This review describes the factors that contribute to maximizing the production of effective mRNA vaccine transcripts and delivery systems, and the clinical applications are discussed in detail.

Details

1009240
Business indexing term
Title
mRNA-Based Vaccines
Author
Kowalzik, Frank 1   VIAFID ORCID Logo  ; Schreiner, Daniel 1   VIAFID ORCID Logo  ; Jensen, Christian 1   VIAFID ORCID Logo  ; Teschner, Daniel 2 ; Gehring, Stephan 1 ; Zepp, Fred 1 

 Pediatric Department, University Medical Center of the Johannes Gutenberg-University, 55128 Mainz, Germany; [email protected] (D.S.); [email protected] (C.J.); [email protected] (S.G.); [email protected] (F.Z.) 
 Department of Hematology, Medical Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University, 55122 Mainz, Germany; [email protected] 
Publication title
Vaccines; Basel
Volume
9
Issue
4
First page
390
Publication year
2021
Publication date
2021
Publisher
MDPI AG
Place of publication
Basel
Country of publication
Switzerland
e-ISSN
2076393X
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Online publication date
2021-04-15
Milestone dates
2021-03-17 (Received); 2021-04-13 (Accepted)
Publication history
 
 
   First posting date
15 Apr 2021
ProQuest document ID
2528258239
Document URL
https://www.proquest.com/scholarly-journals/mrna-based-vaccines/docview/2528258239/se-2?accountid=208611
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2024-10-07
Database
ProQuest One Academic